Upstream Short Term Debt from 2010 to 2026
| UPB Stock | 14.69 13.12 47.18% |
Short Term Debt | First Reported 2010-12-31 | Previous Quarter 809.6 K | Current Value 850.1 K | Quarterly Volatility 278.1 K |
Check Upstream Bio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Upstream Bio's main balance sheet or income statement drivers, such as Net Interest Income of 14.6 M, Interest Income of 14.6 M or Depreciation And Amortization of 57.2 K, as well as many indicators such as Price To Sales Ratio of 495, Dividend Yield of 0.0 or PTB Ratio of 1.7. Upstream financial statements analysis is a perfect complement when working with Upstream Bio Valuation or Volatility modules.
Upstream | Short Term Debt | Build AI portfolio with Upstream Stock |
Analyzing Upstream Bio's Short Term Debt over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Short Term Debt has evolved provides context for assessing Upstream Bio's current valuation and future prospects.
Latest Upstream Bio's Short Term Debt Growth Pattern
Below is the plot of the Short Term Debt of Upstream Bio over the last few years. It is Upstream Bio's Short Term Debt historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Upstream Bio's overall financial position and show how it may be relating to other accounts over time.
| Short Term Debt | 10 Years Trend |
|
Short Term Debt |
| Timeline |
Upstream Short Term Debt Regression Statistics
| Arithmetic Mean | 208,216 | |
| Geometric Mean | 123,398 | |
| Coefficient Of Variation | 133.55 | |
| Mean Deviation | 204,592 | |
| Median | 87,000 | |
| Standard Deviation | 278,063 | |
| Sample Variance | 77.3B | |
| Range | 805.1K | |
| R-Value | 0.65 | |
| Mean Square Error | 47.4B | |
| R-Squared | 0.43 | |
| Significance | 0 | |
| Slope | 35,919 | |
| Total Sum of Squares | 1.2T |
Upstream Short Term Debt History
About Upstream Bio Financial Statements
Upstream Bio stakeholders use historical fundamental indicators, such as Upstream Bio's Short Term Debt, to determine how well the company is positioned to perform in the future. Although Upstream Bio investors may analyze each financial statement separately, they are all interrelated. For example, changes in Upstream Bio's assets and liabilities are reflected in the revenues and expenses on Upstream Bio's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Upstream Bio. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Short Term Debt | 809.6 K | 850.1 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Upstream Bio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Upstream Bio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Upstream Bio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Upstream Bio Stock:Check out the analysis of Upstream Bio Correlation against competitors. For information on how to trade Upstream Stock refer to our How to Trade Upstream Stock guide.You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Upstream Bio. If investors know Upstream will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Upstream Bio assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (6.40) | Revenue Per Share | Quarterly Revenue Growth 0.125 | Return On Assets | Return On Equity |
The market value of Upstream Bio is measured differently than its book value, which is the value of Upstream that is recorded on the company's balance sheet. Investors also form their own opinion of Upstream Bio's value that differs from its market value or its book value, called intrinsic value, which is Upstream Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Upstream Bio's market value can be influenced by many factors that don't directly affect Upstream Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Upstream Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Upstream Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Upstream Bio's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.